Provided by Tiger Trade Technology Pte. Ltd.

Day One Biopharmaceuticals Inc.

9.97
+1.2113.81%
Post-market: 9.84-0.1300-1.30%19:29 EST
Volume:5.18M
Turnover:51.76M
Market Cap:1.02B
PE:-6.76
High:10.47
Open:8.80
Low:8.74
Close:8.76
52wk High:13.53
52wk Low:5.64
Shares:102.68M
Float Shares:78.77M
Volume Ratio:1.62
T/O Rate:6.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4748
EPS(LYR):-1.0243
ROE:-30.16%
ROA:-18.57%
PB:2.27
PE(LYR):-9.73

Loading ...

Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial

Reuters
·
Nov 10

Day One Announces New Ojemda™ (Tovorafenib) Data to Be Presented in Oral Session at the 2025 Society for Neuro-Oncology (Sno) Annual Meeting

THOMSON REUTERS
·
Nov 10

A NEW DAWN OF HOLISTIC WELLNESS AT THE RITZ-CARLTON SPA SINGAPORE: REDEFINING LUXURY WITH THE FUTURE OF SKINCARE

prnewswire
·
Nov 06

Day One Biopharmaceuticals Up Nearly 26%, on Pace for Largest Percent Increase Since June 2022 -- Data Talk

Dow Jones
·
Nov 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: PROCEPT BioRobotics (PRCT), Day One Biopharmaceuticals (DAWN) and Exelixis (EXEL)

TIPRANKS
·
Nov 06

Day One Biopharm Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Nov 05

Stock Track | Day One Biopharmaceuticals (DAWN) Soars 8.29% on Strong Q3 Results and Analyst Endorsement

Stock Track
·
Nov 05

Stock Track | Day One Biopharmaceuticals (DAWN) Soars 6.30% Pre-market on Strong Q3 Results and Analyst Upgrade

Stock Track
·
Nov 05

Stock Track | Day One Biopharmaceuticals (DAWN) Surges 6.30% Pre-market on Strong Q3 Results and Analyst Endorsement

Stock Track
·
Nov 05

H.C. Wainwright Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Nov 05

Day One Biopharmaceuticals Reports Strong Q3 2025 Growth

TIPRANKS
·
Nov 05

Day One Biopharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 05

BRIEF-Day One Biopharmaceuticals Q3 EPS USD -0.19

Reuters
·
Nov 05

Day One Biopharmaceuticals reports third quarter OJEMDA net product revenue of $38.5 million

Reuters
·
Nov 05

Day One Biopharmaceuticals Inc - Raises Ojemda Full-Year 2025 Net Product Revenue Guidance to $145-$150 Mln

THOMSON REUTERS
·
Nov 05

Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

THOMSON REUTERS
·
Nov 05

Day One Biopharmaceuticals Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Nov 01

Day One Biopharmaceuticals Advances Pediatric Cancer Study with Promising Drug Tovorafenib

TIPRANKS
·
Oct 28

Day One Biopharmaceuticals Inc. to Report Third Quarter 2025 Results

Reuters
·
Oct 21

JonesTrading Reaffirms Their Buy Rating on Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Oct 17